BC ADM Cardiometabolic Conditions & Comorbidity Management

Question 1

A 58-year-old patient with type 2 diabetes has blood pressure readings of 142/88 mmHg at two separate clinic visits. According to ADA Standards of Medical Care, what is the recommended blood pressure target for most patients with diabetes and hypertension?

Accepted Answer

Less than 130/80 mmHg

Answer

The ADA recommends a blood pressure target of <130/80 mmHg for most patients with diabetes and hypertension, as this threshold is associated with reduced risk of cardiovascular events, stroke, and nephropathy progression compared to the older <140/90 target.

Question 2

Which antihypertensive medication class is considered first-line for a patient with type 2 diabetes, hypertension, and persistent albuminuria (urine albumin-to-creatinine ratio >300 mg/g)?

Accepted Answer

ACE inhibitors or ARBs

Answer

ACE inhibitors and ARBs are first-line for patients with diabetes and albuminuria because they reduce intraglomerular pressure and have nephroprotective effects beyond their antihypertensive action, slowing progression of diabetic kidney disease.

Question 3

A patient with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD) is being evaluated for statin therapy. What is the recommended LDL-C goal or reduction target according to current ADA guidelines?

Accepted Answer

Reduce LDL-C by at least 50% or achieve LDL-C below 70 mg/dL

Answer

For patients with diabetes and established ASCVD (very high risk), the ADA recommends high-intensity statin therapy with a goal of ≥50% LDL-C reduction OR an LDL-C below 70 mg/dL. If this target is not achieved with maximally tolerated statin therapy, adding ezetimibe or a PCSK9 inhibitor may be considered.

Question 4

A patient with type 2 diabetes and heart failure with reduced ejection fraction (HFrEF, EF 35%) needs improved glycemic control. Which medication class is recommended by both ADA and cardiology guidelines for dual benefit in glycemic control and heart failure outcomes?

Accepted Answer

SGLT2 inhibitors

Answer

SGLT2 inhibitors (empagliflozin, dapagliflozin) have demonstrated significant reductions in heart failure hospitalizations and cardiovascular mortality in patients with HFrEF in landmark trials (EMPEROR-Reduced, DAPA-HF), in addition to their glucose-lowering effects. They are now recommended by both ADA and cardiology guidelines for this population.

Question 5

A patient with type 2 diabetes presents with a fasting triglyceride level of 540 mg/dL. Before initiating statin therapy for cardiovascular risk reduction, what is the primary treatment priority?

Accepted Answer

Lower triglycerides first to reduce the risk of acute pancreatitis

Answer

When triglycerides exceed 500 mg/dL, the immediate priority is reducing triglyceride levels to prevent acute pancreatitis, a serious and potentially life-threatening complication. Fibrates or high-dose omega-3 fatty acids are first-line for severe hypertriglyceridemia. Statin therapy for ASCVD risk reduction becomes the focus once triglycerides are below 500 mg/dL.

(BC ADM) Advanced Diabetes Management Certification Practice Test

(BC ADM) Advanced Diabetes Management Certification Practice Test

BC ADM Cardiometabolic Conditions & Comorbidity Management